Search Results

Aclipse Therapeutics announced today that it has signed an exclusive license agreement with Seoul, South Korea-based Chong Kun Dang Pharmaceutical Corporation (“CKD”).

Healis Therapeutics, a privately held biotechnology company, is thrilled to share that strategic partner, Chong Kun Dang Bio (063160:Korea SE), has released topline results from Phase III on Healis’ lead compound, CKDB-501A.

For $80 million upfront and the promise of more than $1.2 billion in milestones, Novartis has bought the global rights to develop an oral HDAC6 inhibitor from Chong Kun Dang Pharmaceutical.

Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.

OSE Immunotherapeutics, announced a new licensing deal with Chong Kun Dang Pharmaceutical Corporation for Tedopi®, a combination of neoepitopes selected and optimized from five tumor antigens shown to generate a specific response of cytotoxic T cells versus cancer cells expressing at least one of these tumor associated antigens and an associated T-helper cell response, for potential registration and commercialization in Korea.

InflaRx N.V. today announced the appointment of Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023.

Menagen Pharmaceutical Industries and Chong Kun Dang Pharmaceutical Corp Korea announced that they have entered into a strategic partnership in the GCC market for the technology transfer and commercialization for the first biosimilar Darbepoetin alpha, a second-generation epoetin indicated for the treatment of anemia associated with chronic renal failure.